替沙格韦单抗/西加韦单抗预防与自身免疫病患者COVID-19发病率和严重程度降低相关
这项多中心观察性研究纳入115例对疫苗接种无反应(抗SARS-CoV-2抗体<260结合抗体单位/ml)的自身免疫或炎症性疾病患者,在2021年12月至2022年8月期间接受替沙格韦单抗/西加韦单抗暴露前预防。中位随访128天,COVID-19发生于23/115例(20%),所有病例均为非重型;两剂注射方案组感染风险低于单剂注射组[16/49(33%)vs 5/64(8%),P=0.0012]。
要点
- 115例自身免疫或炎症性疾病患者接受替沙格韦单抗/西加韦单抗暴露前预防,中位随访128天COVID-19发生率20%。
- 所有COVID-19病例均为非重型,注射耐受性极好。
- 两剂注射方案组感染16/49(33%)vs 单剂注射组5/64(8%),P=0.0012。
核心结论
- 在对疫苗接种无反应、有重型COVID-19风险的自身免疫或炎症性疾病人群中,替沙格韦单抗/西加韦单抗暴露前预防与COVID-19发病率降低相关且无重型感染。
研究设计与样本
- 多中心观察性研究,纳入2021年12月至2022年8月期间接受替沙格韦单抗/西加韦单抗暴露前预防的自身免疫或炎症性疾病患者115例,中位年龄62岁(IQR 52-71)。
主要发现
- 中位随访128天(IQR 93-173)期间,COVID-19发生于23/115例(20%),8例基因分型患者均鉴定为奥密克戎变异株。
- 研究期间,法兰西岛大区每周平均发病率为1071/100000居民,而本研究患者为588/100000。
- 两剂注射方案组感染16/49(33%)vs 单剂注射组5/64(8%),P=0.0012,两剂方案组感染风险更低。
- COVID-19阳性患者与未感染患者在年龄、合并症、基础风湿病和免疫抑制剂方面无差异。
- 所有COVID-19病例均为非重型,注射耐受性极好。
关键数值与推荐
- 纳入标准为对疫苗接种无反应,即抗SARS-CoV-2抗体<260结合抗体单位/ml。
- 基础免疫抑制剂主要包括利妥昔单抗(n=98)、糖皮质激素[n=62;中位剂量5 mg(95%CI 5-8)]和甲氨蝶呤(n=48)。
- 基础疾病为慢性关节炎(n=53)、结缔组织病(n=38)或血管炎(n=11)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the clinical efficacy of tixagevimab/cilgavimab in pre-exposure prophylaxis in patients at risk of severe coronavirus disease 2019 (COVID-19) and unresponsive to vaccination (anti-severe acute respiratory syndrome coronavirus 2 antibodies <260 binding antibody units/ml) in rheumatology. METHODS: In this multicentre observational study we included patients with autoimmune or inflammatory diseases who received pre-exposure prophylaxis with tixagevimab/cilgavimab between December 2021 and August 2022. The endpoint was incidence of COVID-19 and its severity. RESULTS: Tixagevimab/cilgavimab was administered to 115 patients with a median age of 62 years [interquartile range (IQR) 52-71], chronic arthritis (n = 53), connective tissue disease (n = 38) or vasculitis (n = 11). The main background immunosuppressants were rituximab (n = 98), corticosteroids [n = 62; median dose 5 mg (95% CI 5-8)] and methotrexate (n = 48). During a median follow-up of 128 days (IQR 93-173), COVID-19 occurred in 23/115 patients (20%) and the omicron variant was identified for the eight genotyped patients. During the study period, the average weekly incidence was 1071/100 000 inhabitants in Île-de-France vs 588/100 000 in our patients. Patients who received a two-injection regimen had a lower risk of infection than those with a single injection [16/49 (33%) vs 5/64 (8%), P = 0.0012]. The COVID-19-positive patients did not differ from uninfected patients concerning age, comorbidities, underlying rheumatic disease and immunosuppressants. All COVID-19 cases were non-severe. The tolerance of injections was excellent. CONCLUSION: In a population with autoimmune or inflammatory diseases at risk of severe COVID-19 unresponsive to vaccination, pre-exposure prophylaxis withy tixagevimab/cilgavimab was associated with a lower incidence of COVID-19 and no severe infections.
引用
- Thomas M, Masson M, Bitoun S, et al. Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases. Rheumatology (Oxford). 2024. PMID: 37632774. doi:10.1093/rheumatology/kead449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。